首页> 美国卫生研究院文献>British Journal of Cancer >The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer
【2h】

The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer

机译:雄激素调节基因人类激肽释放酶15(KLK15)是乳腺癌的独立且有利的预后指标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Many kallikrein genes were found to be differentially expressed in various malignancies, and prostate specific antigen (encoded by the KLK3 gene) is the best tumour marker for prostate cancer. Prostate specific antigen has recently been shown to be an independent favourable prognostic marker for breast cancer. KLK15 is newly discovered kallikrein gene that is located adjacent to KLK3 on chromosome 19q13.4. KLK15 has 41% similarity to KLK3 and the encoded protein, hK15, can activate pro-prostate specific antigen. We studied the expression of KLK15 by real-time quantitative reverse transcriptase–polymerase chain reaction in 202 tissues from patients with breast carcinoma of various stages, grades and histological types. KLK15 expression was found to be a significant predictor of progression-free survival (hazard ratio of 0.41 and P=0.011) and overall survival (hazard ratio of 0.34 and P=0.009). When all other known confounders were controlled in the multivariate analysis, KLK15 retained its prognostic significance. Higher concentrations of KLK15 mRNA were found more frequently in node negative patients (P=0.042). No association was found between KLK15 expression and any other clinicopathological variable. Further, KLK15 is an independent prognostic factor of progression-free survival and overall survival in the subgroup of patients with lower grade and those with oestrogen receptor and progesterone receptor negative tumours in both univariate and multivariate analysis. KLK15 levels of expression were slightly higher (although not statistically significant) in the oestrogen receptor negative and progesterone receptor negative subgroups of patients. KLK15 is up-regulated by androgens in breast cancer cell lines. Time-course and blocking experiments suggest that this regulation is mediated through the androgen receptor.British Journal of Cancer (2002) >87, 1294–1300. doi:
机译:发现许多激肽释放酶基因在各种恶性肿瘤中差异表达,并且前列腺特异性抗原(由KLK3基因编码)是前列腺癌的最佳肿瘤标志物。前列腺特异性抗原最近已被证明是乳腺癌的独立有利的预后标志物。 KLK15是新发现的激肽释放酶基因,位于染色体19q13.4上与KLK3相邻。 KLK15与KLK3有41%的相似性,编码的蛋白hK15可以激活前列腺特异性抗原。我们通过实时定量逆转录酶-聚合酶链反应研究了来自不同阶段,级别和组织学类型的乳腺癌患者的202个组织中的KLK15的表达。发现KLK15表达是无进展生存(危险比0.41,P = 0.011)和总生存(危险比0.34,P = 0.009)的重要预测指标。当在多元分析中控制所有其他已知的混杂因素时,KLK15保留了其预后意义。在淋巴结阴性的患者中发现KLK15 mRNA的浓度更高(P = 0.042)。 KLK15表达与任何其他临床病理变量之间未发现关联。此外,在单变量和多变量分析中,KLK15是低级患者以及雌激素受体和孕激素受体阴性肿瘤亚组中无进展生存和总体生存的独立预后因素。在患者的雌激素受体阴性和孕激素受体阴性亚组中,KLK15的表达水平略高(尽管无统计学意义)。 KLK15在乳腺癌细胞系中被雄激素上调。时程和阻断实验表明,这种调节是通过雄激素受体介导的。 British Journal of Cancer (2002)> 87 ,1294–1300。土井:

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号